A recent industry report highlights YIDU TECH (02158) as a key case study. The "2026 Healthcare Large Language Model Application Value Product Ranking" (Top 10), released concurrently, features the company's "Yidu Zhi Xun" (a clinician-focused, evidence-based intelligent agent) alongside products from iFlytek, JD.com, Neusoft, and Ant Group. The ranking's release comes at a pivotal inflection point for China's healthcare LLM sector. Following the initial frenzy after ChatGPT's debut, which saw hundreds of models launched, the industry entered an awkward "suspended" state. General-purpose LLMs proved unsuitable for serious medical applications due to "hallucination" issues, leading to clinician reluctance and stalling commercialization. The report notes that by the end of 2025, 352 vertical medical LLMs had been released in China, but new releases plateaued in the latter half of the year, signaling the end of the land-grab era. The industry focus has shifted from "filling gaps" to "optimizing performance," with capital flowing towards companies demonstrating clear application scenarios and strong implementation capabilities. As the tide recedes, truly capable players are emerging. YIDU TECH's inclusion is no accident. The company, with its strategic goal of building "the AI operating system for hospitals," is among the first to establish a complete closed loop from technology validation to commercial monetization, evidenced by deep collaborations and recurring purchases from top-tier hospitals.
With the bubble receding, where does "most application value" come from? The ranking criteria reflect a fundamental shift in the industry's evaluation system. The report emphasizes that healthcare LLMs have entered the "year of implementation," making the practical application of technology and products the core theme. "Application value" is no longer about leaderboard metrics but is defined by usage frequency, user stickiness, and willingness to pay in real clinical settings. The report's rationale for "Yidu Zhi Xun" aligns clearly with this. In the "Clinical Department Scenarios" section, it mentions that YIDU TECH launched "Yidu Zhi Xun" in 2026 as an evidence-based assistant for clinicians, supporting diagnosis, treatment, and research by enabling rapid queries of guidelines, drug information, cancer staging, clinical trials, and latest advancements, significantly improving retrieval and evidence-based decision efficiency. The report further discloses that solutions built on the "Yidu Zhi Xun" evidence engine have been deployed in over 50 top-tier hospitals, participating deeply in over 500,000 clinical decisions, and have received high recognition from authoritative institutions like Peking Union Medical College Hospital and Sun Yat-sen University Cancer Center. This data is particularly valuable in the current context. Research indicates many AI products stall at the "demo" stage, abandoned by clinicians in practice due to inability to handle complex cases or integrate with heterogeneous systems. The high-frequency use of "Yidu Zhi Xun" in frontline clinical work itself provides the answer—it addresses real clinician pain points.
Analyzing the "core prerequisites for serious medical LLM implementation," the report stresses that companies must overcome three major hurdles: performance optimization (reducing hallucinations), regulatory compliance, and trust endorsement. "Trust endorsement" is especially critical: products need clinical authority recognition, with usage methods integrated into clinical guidelines or industry standards. The report's fourth chapter reveals that YIDU TECH has jointly developed over 280 specialized disease-specific intelligent agents with top institutions including Peking Union Medical College Hospital, Sun Yat-sen University Cancer Center, Peking University Cancer Hospital, and Tsinghua Chang Gung Hospital, covering areas like cardiovascular, oncology, and hematology. This is the most direct manifestation of "trust endorsement"—when experts from top hospitals are willing to use their own data to "train" the AI, the product's irreplaceability is established.
The "Trust Votes" from Hospitals like Peking Union and Xiangya: From Entry to Repurchase In the medical AI industry, "hospital entry" is often seen as a success marker. However, a one-time project win is not the true test; the real measure is a hospital's willingness for continuous payment, upgrades, and deeper collaboration. The report mentions in the "Extra-hospital Business Models" section that YIDU TECH won the Hainan Provincial Public Health Emergency Platform project in 2026, using AI to enhance provincial infectious disease surveillance and emergency coordination. But this is just the tip of the iceberg. The real foundation of its commercial closed loop is deep-rooted presence at the top hospital level. Peking Union Medical College Hospital is the "gold standard" of Chinese healthcare; any product gaining its recognition has passed the most stringent test. The report discloses that YIDU TECH's evidence engine has received authoritative recognition from Peking Union. More notably, this recognition is not a "one-off"—the collaboration has expanded from a single product to the joint development of multiple specialized intelligent agents, evolving from "project delivery" to "capability symbiosis." Central South University Xiangya Hospital is another compelling case. In February 2025, Xiangya Hospital successfully completed the localized deployment of a domestic AI medical middleware platform developed by YIDU TECH, becoming the first hospital in China to deploy such a system. As reported, the platform's innovation lies in "four opens"—technology, data, service, and ecosystem openness—achieving autonomy from hardware to software based on Ascend GPUs. The depth of this collaboration stems from continuous cultivation since 2019: the two parties have jointly built an artificial joint registry system, a gynecological oncology big data platform, a hospital-wide scientific research data platform, and other projects. Xiangya Hospital has aggregated over 2.5 billion medical data points, forming more than 10 specialized disease databases. The trajectory from specialized databases to a hospital-wide research platform, and then to localized AI middleware deployment, clearly shows Xiangya's path of "repurchase." In top-tier oncology, YIDU TECH's presence is equally deep. In May 2026, an affiliate of YIDU TECH won the bid for the Sun Yat-sen University Cancer Center's Smart Clinical and Settlement Service Upgrade Project, valued at approximately 9.08 million RMB. This is not an ordinary order but another "repurchase" following continuous cooperation since 2015. The partners had previously built China's first T+0 real-time updated oncology big data platform, integrating over 30 core systems and covering full-course data for 2 million patients. In February 2026, the private deployment of the AI middleware platform landed at the center—from big data platform to AI middleware to smart clinical system, the center's consecutive choices signify that YIDU TECH's products are deeply embedded into the fabric of this top cancer hospital. Also noteworthy is Peking University Cancer Hospital. In April 2026, YIDU TECH won the bid for the hospital's AI Construction Bank-Hospital Cooperation Project, valued at approximately 4.88 million RMB. At the clinical implementation level, YIDU TECH's Level 3 traceable medical record generation intelligent agent is in regular use at Peking University Cancer Hospital. Its "knowledge + fact" dual-constraint architecture ensures every AI suggestion is traceable to original data sources—a design addressing the biggest pain point of AI in serious medical scenarios: accountability. Thus, YIDU TECH has achieved precise coverage: with Peking Union Medical College Hospital as the northern flagship, Central South University Xiangya Hospital as the southern stronghold, and top specialized hospitals like Sun Yat-sen University Cancer Center and Peking University Cancer Hospital as the depth of its阵地. The long-term trust represented by this "repurchase" and "deep embedding" far exceeds any advertising rhetoric.
Profit Inflection Point: The Final Touch for the Commercial Closed Loop If technological strength is the "substance," then financial data is the "appearance." On April 20, 2026, YIDU TECH issued a positive profit alert, forecasting a net profit of approximately 55 to 70 million RMB for the 2026 fiscal year. This marks the company's first annual profit since its founding 11 years ago, a significant reversal from the 135 million RMB net loss in the 2025 fiscal year. The core logic supporting this profitability is the continuous product upgrade following AI integration. The announcement notes that incorporating AI capabilities effectively enhanced product value propositions and competitiveness, driving significant new order growth in core business segments. A higher value-added product mix, improved operational efficiency, and economies of scale jointly contributed to increased gross margins. Looking at the order structure, YIDU TECH's revenue sources have diversified: B-end (hospitals) feature continuous cooperation and repurchases from top institutions like Peking Union, Xiangya, Sun Yat-sen University Cancer Center, and Peking University Cancer Hospital; G-end (government) includes provincial projects like the Hainan Provincial Coordinated Regional Infectious Disease Surveillance and Early Warning Platform (nearly 12.89 million RMB) and the Hainan Smart Health Island Construction Project (approx. 14.76 million RMB); overseas markets feature expansions like the Singapore Dr. Buddy project (approx. 12.20 million RMB). The report points out that capital is concentrating on companies with clear application scenarios and strong implementation capabilities. The increase in later-stage financing rounds and average deal size signals the industry's transition from rapid growth to mature development. YIDU TECH's first profit precisely confirms this trend—as the industry moves from "storytelling" to "accounting," only players capable of self-sustenance remain at the table.
Conclusion: The "Value Verification Moment" for Medical AI Reviewing YIDU TECH's development history reveals a company tempered through multiple industry cycles. Over more than a decade of dramatic medical digitalization, it has consistently remained at the forefront of data governance and AI application. The report indicates that future healthcare LLMs will trend towards "specialized深耕 within hospitals, diversified integration outside hospitals." YIDU TECH's布局恰好 aligns with this prediction—downwards, through apex clients like Peking Union, Xiangya, and Sun Yat-sen University Cancer Center, it hones specialized capabilities to the extreme, jointly creating over 280 specialized disease intelligent agents with top hospitals; upwards, through products like "Yidu Zhi Xun," it democratizes the intelligent capabilities of evidence-based medicine to a broader clinician base. The inclusion of "Yidu Zhi Xun" in the "2026 Healthcare AI Large Model Most Valuable Application Product Ranking" and the "votes with money" from top medical institutions like Peking Union, Xiangya, Sun Yat-sen University Cancer Center, and Peking University Cancer Hospital mark the formal transition of China's medical AI from the era of "storytelling" to the era of "accounting"—accounting for cost reduction and efficiency gains, and accounting for clinical value. For YIDU TECH, profitability is just the beginning. As its AI middleware and other innovative products become "standard equipment" in more top-tier hospitals, a new paradigm for AI-driven clinical decision support and evidence-based medicine intelligence is being quietly written.
Comments